Industry News
Biotechnology Industry News
Less than two years after…
Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as the reason for the sudden closure.
The…
The hypertrophic-cardiomyopathy-focused biotech is led by former HI-Bio founder and CEO Travis Murdoch, M.D., while Biogen's CEO Chris Viehbacher chairs the board of directors.
Protara is working to address…
Protara is working to address choline deficiency in patients who are dependent on parenteral nutrition and don’t have available treatment today.
Eli Lilly is doubling down on its…
Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345
Pfizer has axed 11 programs…
Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.
Fueled by public-private…
Fueled by public-private partnerships, talent development, and cutting-edge research, Ohio is emerging as a powerhouse in biotech and healthcare innovation.
Questex has acquired The…
Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence, market research and the future of drug delivery.
As deal-making rebounds in a…
As deal-making rebounds in a volatile year, Waterhouse Brands urges biotech firms to prioritize storytelling, credibility and long-term strategy.
After its cannabidiol gel…
After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease.
The spread of misinformation…
The spread of misinformation remains a major public health and reputational challenge.
Executives from Parexel spotlight…
Executives from Parexel spotlight AI integration, data-driven trial design and workforce transformation.
Pfizer may have launched a…
Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes, the U.S. pharma has shown some willingness to rework its own deal.
PhaseV’s transparent AI platform…
PhaseV’s transparent AI platform helps sponsors reduce trial failures and accelerate drug development through smarter design and real-world data integration.
Merck & Co. began Tuesday with…
Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive pivotal oncology push.
The precision oncology biotech is…
The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.
Nuvation Bio has backed off from…
Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier's Voranigo, instead opting to focus on patients who aren’t covered by the approved competitor.
Korean biosimilar specialist…
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune assets from U.S. biotech Kaigene.
A new West Coast biotech has…
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed with $82 million
Foresight Diagnostics shared…
Foresight Diagnostics shared insights into the evolving role of minimal residual disease (MRD) testing in precision oncology.
AI-powered platform streamlines…
AI-powered platform streamlines regulatory processes, boosts collaboration and accelerates drug development timelines.